Sands Capital

Hawk is an award-winning provider of AI-supported anti-money laundering and fraud detection technology. Banks, payment providers, and fintechs globally are using Hawk’s powerful combination of traditional rules and explainable AI to improve the effectiveness of their AML compliance and fraud prevention. Hawk monitors and screens billions of transactions across 60 countries evey year.

Flock Safety is a company that specializes in security solutions through the use of automated license plate recognition (ALPR) cameras. Its primary product, the ALPR camera system, is designed for use by neighborhoods, law enforcement agencies, and businesses to capture and analyze vehicle license plates. This technology aids in both preventing and solving crimes by providing actionable data to local authorities. Flock Safety's platform emphasizes community collaboration, integrating efforts from cities, businesses, schools, and law enforcement to enhance public safety. The company's full-service, maintenance-free technology is trusted by various communities as a means to deter crime and promote a safer environment for residents. Additionally, the system proactively alerts police when stolen vehicles enter monitored areas, enabling faster response and community involvement in crime prevention.

PgEdge is a technology company that specializes in distributed PostgreSQL, focusing on optimizing network edge performance to minimize data latency and ensure ultra-high availability. The company provides a fully managed cloud service that leverages multi-active, multi-master, and multi-region capabilities. This innovative approach enables developers to easily build and deploy highly distributed database applications across a global network. PgEdge's solutions are particularly suited for mission-critical applications that require reliable and efficient data management across diverse geographic locations.

CompScience is a technology company that specializes in AI-driven solutions for the workers' compensation insurance sector, with a primary focus on enhancing workplace safety. The company develops a platform that utilizes machine learning algorithms to analyze historical data, allowing organizations to assess their safety protocols, identify potential hazards, and implement effective risk management strategies. By providing actionable insights, safety monitoring, and a user-friendly dashboard, CompScience helps businesses in logistics and manufacturing industries reduce injuries and lower workers' compensation costs. Additionally, the platform facilitates improved communication between safety teams and management, ensuring that safety initiatives align with organizational objectives and ultimately enhance employee well-being and operational performance.

Dreadnode is a specialized company that operates in the field of offensive machine learning, primarily focusing on cybersecurity. It offers a range of services aimed at conducting research, evaluations, and creating cyber ranges to enhance the effectiveness of machine learning applications against AI systems. Dreadnode develops assessment methodologies and tools that facilitate offensive engagements, helping clients identify and mitigate vulnerabilities in their systems. By providing these services, the company enables users to maintain their systems in a risk-free environment, thereby strengthening their cybersecurity posture.

Fire1 is a Dublin-based company dedicated to developing innovative therapeutic devices aimed at enhancing the quality of life for heart failure patients. The company has created a remote monitoring system that delivers real-time patient data and insights to healthcare providers. This technology facilitates the early detection of complications associated with heart failure, allowing for proactive interventions and ultimately leading to improved patient outcomes. Through its focus on remote monitoring, Fire1 seeks to transform the management of heart failure and support better health management for patients.

Databricks Inc. is a technology company that provides a unified data analytics cloud platform designed to facilitate data engineering and collaborative data science. The company offers a comprehensive suite of tools, including a just-in-time data platform that simplifies data integration, real-time experimentation, and deployment of production applications for developers and data scientists. Key products include Databricks Delta, which combines the capabilities of data warehouses with low-latency streaming, MLflow for managing the machine learning lifecycle, and Delta Lake for handling batch and streaming data. Databricks serves a diverse range of industries, including advertising, healthcare, manufacturing, and telecommunications, and has established strategic partnerships with various organizations to enhance its offerings. Founded in 2013, Databricks is headquartered in San Francisco, California, with additional offices in London, Amsterdam, and Bengaluru.

Avenzo Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative therapies for oncology, specifically targeting underserved and rare cancers. The company operates a specialized platform that focuses on creating novel treatments aimed at genomically defined cancer types. By prioritizing targeted therapies, Avenzo Therapeutics seeks to advance cancer treatment options for patients who may not have access to effective solutions, thus addressing significant gaps in the current therapeutic landscape.

Vitara Biomedical develops a therapeutic platform to support premature infants. It offers natural physiological processes and hopes to transform neonatal care for newborns and their families into a lifetime of possibilities.

Beta Bionics is a biotechnology company focused on developing advanced solutions for diabetes management. Its flagship product, the iLet Bionic Pancreas System, is an integrated device designed to alleviate the burden of diabetes care. This system encompasses a dual-chamber infusion pump that delivers insulin and glucagon with precision and accuracy, autonomously calculating and administering doses to help patients maintain optimal blood sugar levels. The iLet has received breakthrough designation for all its configurations, including insulin-only, glucagon-only, and bihormonal, and it incorporates Zealand Pharma’s dasiglucagon, which is known for its stability in a ready-to-use aqueous solution. Through these innovations, Beta Bionics aims to improve the quality of life for individuals living with diabetes.

Blue Earth Therapeutics is a radiopharmaceutical company that specializes in the advancement of next-generation targeted radiotherapeutics to treat cancer patients. It is a sister company of Blue Earth Diagnostics.

CytoVale, Inc. is a medical technology company based in San Francisco, California, established in 2012. The company specializes in developing biomarkers that leverage the mechanical properties of individual cells, a field known as mechanomics. By utilizing microfluidics technology, CytoVale can efficiently route and physically probe single cells to measure multiple biomarkers simultaneously. This innovative approach aims to enhance early detection of immune-mediated diseases, particularly sepsis, thereby improving patient outcomes and reducing treatment costs. CytoVale's integration of cell mechanics with machine learning positions it at the forefront of revolutionizing diagnostic practices in healthcare.

Inhibikase Therapeutics has developed the first small molecule platform capable of treating both bacterial and viral infectious diseases through a common mechanism of action in the host. The company's host targeting strategy creates multi-pathogen anti-infectives without stimulating resistance.

PgEdge is a technology company that specializes in distributed PostgreSQL, focusing on optimizing network edge performance to minimize data latency and ensure ultra-high availability. The company provides a fully managed cloud service that leverages multi-active, multi-master, and multi-region capabilities. This innovative approach enables developers to easily build and deploy highly distributed database applications across a global network. PgEdge's solutions are particularly suited for mission-critical applications that require reliable and efficient data management across diverse geographic locations.

Anduril Industries, Inc. is a defense technology company that designs, manufactures, and deploys advanced hardware and software products to address complex national security challenges faced by the United States and its allies. Founded in 2017 and headquartered in Irvine, California, with additional offices in Washington, D.C., and Seattle, the company employs top technical talent to create innovative solutions. Its offerings include the Lattice Platform, which integrates artificial intelligence, computer vision, and machine learning to provide a cohesive operational picture; the Sentry Tower, which collects data across the electromagnetic spectrum; and the Ghost sUAS, a man-portable unmanned aerial system capable of performing various missions autonomously. Additionally, Anduril develops the Anvil sUAS, designed for precise drone threat interception while providing visual feedback for human operators. Through its cutting-edge technology, Anduril aims to enhance defense capabilities and support frontline personnel in safeguarding national interests.

Credo AI is a company focused on enabling enterprises to responsibly develop, adopt, and utilize artificial intelligence at scale. Founded in 2020, it offers a sophisticated AI governance platform that automates oversight and risk management associated with AI technologies. This platform ensures continuous regulatory compliance with emerging global standards, including the EU AI Act and guidelines from NIST and ISO. By providing tools to measure, monitor, and manage risks linked to AI implementations, Credo AI helps businesses build customer trust, differentiate their offerings, and effectively manage potential challenges. The company has garnered recognition for its innovation, being listed among the CBInsights AI 100 and named a Technology Pioneer by the World Economic Forum, among other accolades.

PolyAI Ltd is a company that specializes in developing a conversational artificial intelligence platform aimed at enhancing human-machine voice interactions. Established in 2017 and headquartered in London, United Kingdom, with an additional office in New York, the company focuses on building enterprise voice assistants that engage in natural conversations with customers to address their needs. The platform utilizes advanced machine learning and natural language processing technologies, enabling it to understand and respond to customers effectively, regardless of the variations in their speech. Key features of PolyAI’s platform include multilingual support, dynamic flow design, and task-agnostic capabilities, allowing developers to create seamless and human-like interactions within various digital environments.

Ramp is a company that specializes in providing modern solutions for financial operations and enterprise content delivery. Its financial platform includes tools for corporate card management, expense tracking, bill payments, and seamless accounting integrations, aimed at helping organizations optimize their financial tasks and reduce costs. Additionally, Ramp offers advanced video management and delivery software, enabling companies to enhance video content discovery, user engagement, and secure delivery. Its products, such as VideoVerge and AltitudeCDN, leverage innovative technologies like speech-to-text and natural language processing to create rich metadata for video assets, allowing them to be effectively integrated into popular content management systems. Ramp serves a diverse clientele, including prominent media companies and organizations across various industries such as healthcare, finance, and technology. Founded in 1948 and based in Boston, Massachusetts, Ramp operates as a subsidiary of Raytheon BBN Technologies Corporation.

Acrivon Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision oncology therapeutics. The company employs a proteomics-based platform to identify patients whose tumors are likely to respond positively to specific treatments, thereby enhancing the effectiveness of its drug development efforts. Acrivon's pipeline features its lead program, ACR-368 (prexasertib), which is currently in Phase 2 trials, alongside several preclinical programs targeting key components of DNA damage response and cell cycle regulation, including WEE1 and PKMYT1. By concentrating on complex oncology drug targets that are often not addressed by traditional therapies, Acrivon aims to expedite the advancement of both in-licensed clinical-stage assets and its internally developed programs through accelerated registration trials.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, focused on developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. Established in 2014, the company utilizes synthetic amplifier technology to enhance the speed and complexity of antibiotic susceptibility testing, thereby significantly improving patient care. By facilitating the rapid selection of personalized antimicrobial therapies, SeLux aims to transform the management of infectious diseases, ultimately saving lives, reducing hospital stays, and combating the growing issue of antibiotic resistance through more targeted treatments.

Avenzo Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative therapies for oncology, specifically targeting underserved and rare cancers. The company operates a specialized platform that focuses on creating novel treatments aimed at genomically defined cancer types. By prioritizing targeted therapies, Avenzo Therapeutics seeks to advance cancer treatment options for patients who may not have access to effective solutions, thus addressing significant gaps in the current therapeutic landscape.

Alamar Biosciences, founded in 2018 and headquartered in Fremont, California, specializes in developing advanced technologies for the early detection and treatment of cancer and other diseases. The company focuses on a precision proteomics platform that facilitates protein analysis and the creation of antibody technologies. This platform is designed to enhance the diagnosis of diseases, particularly cancer, while also supporting the discovery of new biomarkers. By enabling healthcare providers to detect diseases at an early stage, Alamar Biosciences aims to improve patient outcomes through timely interventions and potential cures.

HealthSnap, Inc. is a healthcare technology company that specializes in developing solutions for processing patient lifestyle data. Incorporated in 2015 and based in Miami, Florida, with an additional location in San Mateo, California, HealthSnap offers a comprehensive Virtual Care Management Platform. This platform enables healthcare organizations to enhance patient outcomes and streamline care management through tools such as Remote Patient Monitoring (RPM) and Chronic Care Management (CCM). By standardizing the collection and analysis of lifestyle health data, HealthSnap assists providers in effectively integrating this information to prevent chronic diseases. The company's technology also utilizes artificial intelligence for care coordination and automates billing processes, thereby aiding clinicians in managing and preventing chronic conditions linked to lifestyle factors.

Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.

BioAge Labs, Inc. is a biotechnology company focused on developing therapies to treat aging and age-related diseases. The company utilizes a proprietary systems biology and artificial intelligence platform to identify significant drug targets that influence aging, leveraging extensive datasets to uncover the molecular drivers of age-related pathologies. Among its key offerings is BGE-117, a hypoxia-inducible factor prolyl hydroxylase inhibitor that activates HIF-1 target genes involved in various biological processes, including tissue regeneration and vascular remodeling. Another notable product is BGE-175, an orally administered inhibitor targeting the prostaglandin D2 DP1 signaling pathway, which is linked to an increased risk of mortality and infections, including those associated with immune aging. Founded in 2015 and headquartered in Richmond, California, BioAge Labs is dedicated to harnessing the biology of human aging to create innovative therapies for metabolic and age-related diseases.

LimaCharlie is a developer of a security infrastructure platform that focuses on managing cloud security through a Security Infrastructure as a Service (SIaaS) model. The company's platform offers a comprehensive suite of endpoint-driven information security tools, telemetry storage, and a complete incident response pipeline. It also features a hunting platform and a range of pre-made services, allowing businesses to customize their own detection and response rules. By delivering these security solutions on-demand and at scale, LimaCharlie significantly reduces costs and operational efforts for organizations, enabling them to effectively run Managed Security Service Providers (MSSP) or Security Operations Centers (SOC). Additionally, LimaCharlie provides APIs that empower users to build and monetize their own security products.

Elephas is a company focused on revolutionizing cancer treatment through its innovative live tumor imaging diagnostics platform. By leveraging advances in cancer biology, multimodal microscopy, engineering, and artificial intelligence, Elephas aims to enhance clinical decision-making and personalize therapy for cancer patients. The company's approach involves the use of human live tumor fragments, allowing clinicians to determine the most effective treatment strategies for individual patients. In doing so, Elephas not only seeks to improve patient outcomes but also to expedite the drug development process, addressing the significant challenges faced in oncology.

CytoVale, Inc. is a medical technology company based in San Francisco, California, established in 2012. The company specializes in developing biomarkers that leverage the mechanical properties of individual cells, a field known as mechanomics. By utilizing microfluidics technology, CytoVale can efficiently route and physically probe single cells to measure multiple biomarkers simultaneously. This innovative approach aims to enhance early detection of immune-mediated diseases, particularly sepsis, thereby improving patient outcomes and reducing treatment costs. CytoVale's integration of cell mechanics with machine learning positions it at the forefront of revolutionizing diagnostic practices in healthcare.

SafeRide Health is a healthcare technology platform that focuses on enhancing medical transportation and care coordination for vulnerable populations. The company provides a comprehensive platform that empowers health plans to manage their members effectively, ensuring greater intelligence and control over services. By utilizing advanced technology and artificial intelligence, SafeRide Health facilitates end-to-end data transparency, which in turn improves patient experiences and outcomes. The platform aims to transform the patient journey, enhance population health, and reduce overall healthcare costs through its innovative solutions, including patented fleet management capabilities tailored to the healthcare industry.

Beta Bionics is a biotechnology company focused on developing advanced solutions for diabetes management. Its flagship product, the iLet Bionic Pancreas System, is an integrated device designed to alleviate the burden of diabetes care. This system encompasses a dual-chamber infusion pump that delivers insulin and glucagon with precision and accuracy, autonomously calculating and administering doses to help patients maintain optimal blood sugar levels. The iLet has received breakthrough designation for all its configurations, including insulin-only, glucagon-only, and bihormonal, and it incorporates Zealand Pharma’s dasiglucagon, which is known for its stability in a ready-to-use aqueous solution. Through these innovations, Beta Bionics aims to improve the quality of life for individuals living with diabetes.

Ramp is a company that specializes in providing modern solutions for financial operations and enterprise content delivery. Its financial platform includes tools for corporate card management, expense tracking, bill payments, and seamless accounting integrations, aimed at helping organizations optimize their financial tasks and reduce costs. Additionally, Ramp offers advanced video management and delivery software, enabling companies to enhance video content discovery, user engagement, and secure delivery. Its products, such as VideoVerge and AltitudeCDN, leverage innovative technologies like speech-to-text and natural language processing to create rich metadata for video assets, allowing them to be effectively integrated into popular content management systems. Ramp serves a diverse clientele, including prominent media companies and organizations across various industries such as healthcare, finance, and technology. Founded in 1948 and based in Boston, Massachusetts, Ramp operates as a subsidiary of Raytheon BBN Technologies Corporation.

OneTrust, LLC is a technology company that specializes in privacy management and compliance solutions. Founded in 2016 and headquartered in Atlanta, Georgia, the company offers a comprehensive platform that automates various aspects of privacy program management, including privacy impact assessments, data inventory mapping, and risk remediation actions. OneTrust’s solutions facilitate compliance with global regulations by providing tools for vendor risk management, incident reporting, and website compliance, as well as managing data subject rights and consent. The platform serves a diverse clientele ranging from multinational corporations to small and medium enterprises, allowing them to collaborate effectively on privacy risks associated with customer, employee, and vendor data. OneTrust also provides training and certification programs, ensuring that organizations can maintain continuous compliance through ongoing audits and assessments. With additional offices worldwide, OneTrust is positioned to support businesses in navigating the complexities of privacy regulations across various sectors and jurisdictions.

Luminoah is a medical device company focused on transforming the enteral feeding market through its innovative platform for personalized enteral nutrition. The company has developed a closed-loop system that integrates a wearable device with durable medical equipment and consumable nutrition pouches. This system allows for real-time tracking of feed status online, enabling healthcare professionals to remotely monitor patients and assess clinical outcomes effectively. By enhancing chronic disease care, Luminoah aims to improve the quality of life for individuals requiring enteral nutrition.

Hungry Marketplace Inc. is a Washington, D.C.-based platform that connects independent chefs with businesses seeking high-quality catered meals. Founded by Eman Pahlavani, Shy Pahlevani, and Jeff Grass, the company aims to revolutionize the $60 billion business and events catering market by offering a diverse range of curated menus from local chefs. Hungry's platform facilitates the ordering of office lunches and other meal services. The company is committed to community welfare through its 'Fight Against Hunger' initiative, which donates one meal for every two purchased, and its 'WeRecycle' program, which emphasizes environmental sustainability by using biodegradable serving materials. With operations expanding rapidly in cities such as Philadelphia, Atlanta, Boston, and New York City, Hungry aims to broaden its reach to a total of 23 U.S. cities by the end of 2021.

PgEdge is a technology company that specializes in distributed PostgreSQL, focusing on optimizing network edge performance to minimize data latency and ensure ultra-high availability. The company provides a fully managed cloud service that leverages multi-active, multi-master, and multi-region capabilities. This innovative approach enables developers to easily build and deploy highly distributed database applications across a global network. PgEdge's solutions are particularly suited for mission-critical applications that require reliable and efficient data management across diverse geographic locations.

Hawk is an award-winning provider of AI-supported anti-money laundering and fraud detection technology. Banks, payment providers, and fintechs globally are using Hawk’s powerful combination of traditional rules and explainable AI to improve the effectiveness of their AML compliance and fraud prevention. Hawk monitors and screens billions of transactions across 60 countries evey year.

Snyk Ltd. is a software as a service company that specializes in application security, enabling developers to identify and remediate vulnerabilities within their code and associated components. Founded in 2015 and headquartered in London, Snyk offers a suite of tools designed for modern application development, including Snyk Code for static application security testing, container vulnerability management, and infrastructure as code security solutions. The platform seamlessly integrates into developers' workflows, allowing security teams to collaborate effectively with development teams. Snyk's services encompass monitoring application dependencies for vulnerabilities, ensuring licensing compliance, and providing detailed reports and issue tracking. With a client base of 1,200 organizations, including prominent companies like Google and Salesforce, Snyk empowers developers to build secure applications while enhancing overall security posture and productivity. The company also maintains a strategic partnership with Rapid7, further extending its capabilities in the security landscape.

Tellius, Inc. is an AI-powered business analytics platform established in 2015 and headquartered in Reston, Virginia. The platform is designed to help enterprises accelerate data-driven insights and decision-making by integrating artificial intelligence with a search-enabled interface for ad hoc exploration. Unlike traditional business intelligence tools, Tellius employs a distributed architecture that leverages Apache Spark, enabling it to handle big data efficiently. The platform automates the interpretation and analysis of data through machine learning, identifying hidden correlations, trends, and anomalies. Users can pose questions about their business data and receive immediate insights, which are presented as suggested visualizations and predictive models, facilitating a more comprehensive understanding of their operations.

RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. The company specializes in developing tumor-targeted small molecule medicines that leverage radioisotopes to improve cancer treatment outcomes. RayzeBio focuses on creating innovative radiopharmaceuticals, particularly utilizing alpha-emitting radioisotopes like Actinium-225, to target solid tumors effectively. With a robust pipeline of drug candidates, RayzeBio is committed to addressing significant market opportunities in oncology through late-stage clinical programs, development initiatives, and discovery efforts. The company's mission is to provide effective therapeutic solutions aimed at defeating cancer.

Vitara Biomedical develops a therapeutic platform to support premature infants. It offers natural physiological processes and hopes to transform neonatal care for newborns and their families into a lifetime of possibilities.

Elephas is a company focused on revolutionizing cancer treatment through its innovative live tumor imaging diagnostics platform. By leveraging advances in cancer biology, multimodal microscopy, engineering, and artificial intelligence, Elephas aims to enhance clinical decision-making and personalize therapy for cancer patients. The company's approach involves the use of human live tumor fragments, allowing clinicians to determine the most effective treatment strategies for individual patients. In doing so, Elephas not only seeks to improve patient outcomes but also to expedite the drug development process, addressing the significant challenges faced in oncology.

Cleerly is a healthcare company focused on transforming the management of coronary artery disease through innovative digital care pathways aimed at preventing heart attacks. By combining advanced clinical science with state-of-the-art artificial intelligence, Cleerly develops a platform that delivers actionable clinical insights for all stakeholders involved in heart care. This platform employs a non-invasive approach to analyze and characterize plaque buildup in coronary arteries, allowing healthcare providers to better identify at-risk patients and facilitate early treatment. Cleerly's data-driven solutions not only enhance the evaluation of cardiovascular disease but also aim to improve patient heart health while delivering value to the healthcare system.

Inspirna is a clinical-stage biopharmaceutical company focused on developing innovative drug candidates that target essential drivers of cancer. Utilizing a discovery platform centered on RNA biology, Inspirna identifies novel cancer targets that contribute to tumor growth and disease progression. The company is advancing several first-in-class oral small molecules, including RGX-202, aimed at treating patients with RAS mutant colorectal cancer, and RGX-104, which is in development for small cell lung cancer and non-small cell lung cancer. Through its microRNA-based target discovery approach, Inspirna seeks to provide effective treatment options for cancer patients by employing targeted therapies that leverage small molecules and biologics.

Papercup is a London-based company that specializes in automating the dubbing and translation of video content using advanced artificial intelligence. Its software employs a combination of Bayesian neural networks and speech synthesis to create synthetic voice-overs that closely resemble human speech. This technology allows video creators to produce content in their original language while enabling users to translate videos into their preferred languages. Papercup's platform streamlines the localization process, making it faster and more cost-effective compared to traditional methods. The company also incorporates a quality assurance system where professional translators review the voiceovers, ensuring high accuracy and broadcast-quality results. By enhancing video accessibility, Papercup aims to help content owners engage with a global audience more effectively.

LimaCharlie is a developer of a security infrastructure platform that focuses on managing cloud security through a Security Infrastructure as a Service (SIaaS) model. The company's platform offers a comprehensive suite of endpoint-driven information security tools, telemetry storage, and a complete incident response pipeline. It also features a hunting platform and a range of pre-made services, allowing businesses to customize their own detection and response rules. By delivering these security solutions on-demand and at scale, LimaCharlie significantly reduces costs and operational efforts for organizations, enabling them to effectively run Managed Security Service Providers (MSSP) or Security Operations Centers (SOC). Additionally, LimaCharlie provides APIs that empower users to build and monetize their own security products.

Redbud Brands is a brand development studio that specializes in creating and scaling innovative consumer companies, particularly in the premium consumer packaged goods sector. The company collaborates with visionary founders and executives to develop disruptive brands that prioritize 'better-for-you' products. Redbud Brands offers a comprehensive platform that includes access to capital, a shared services network featuring experienced executives, and strategic relationships with retailers, distributors, and suppliers. This approach empowers entrepreneurs to launch and grow impactful brands that aim to make a positive contribution to society while achieving sustainable business success.

Credo AI is a company focused on enabling enterprises to responsibly develop, adopt, and utilize artificial intelligence at scale. Founded in 2020, it offers a sophisticated AI governance platform that automates oversight and risk management associated with AI technologies. This platform ensures continuous regulatory compliance with emerging global standards, including the EU AI Act and guidelines from NIST and ISO. By providing tools to measure, monitor, and manage risks linked to AI implementations, Credo AI helps businesses build customer trust, differentiate their offerings, and effectively manage potential challenges. The company has garnered recognition for its innovation, being listed among the CBInsights AI 100 and named a Technology Pioneer by the World Economic Forum, among other accolades.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, focused on developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. Established in 2014, the company utilizes synthetic amplifier technology to enhance the speed and complexity of antibiotic susceptibility testing, thereby significantly improving patient care. By facilitating the rapid selection of personalized antimicrobial therapies, SeLux aims to transform the management of infectious diseases, ultimately saving lives, reducing hospital stays, and combating the growing issue of antibiotic resistance through more targeted treatments.

Red Sift is a cybersecurity company that specializes in enhancing organizations' digital resilience through its comprehensive Digital Resilience Platform. This platform is designed to address vulnerabilities across an organization's entire digital footprint, offering advanced discovery and monitoring capabilities for email, domains, brand protection, and network perimeter security. By leveraging machine learning, Red Sift provides users with tools to analyze and synthesize data, enabling proactive threat detection and effective remediation strategies against phishing attacks while ensuring compliance with web security protocols. With a diverse client base that includes notable companies such as Domino’s, ZoomInfo, and various global law firms, Red Sift operates globally with offices in North America, Australia, Spain, and the UK, and collaborates with trusted partners like Entrust and Microsoft to enhance its offerings.

Speech Graphics Ltd is a company based in Edinburgh, United Kingdom, specializing in procedural facial animation technology for the entertainment industry. Founded in 2010, the company emerged from the University of Edinburgh's School of Informatics and has leveraged over 20 years of research and development in speech technology and facial dynamics. Speech Graphics offers SGX, a production software that transforms audio files and transcripts into high-quality facial animations without the need for motion capture. Their technology has been utilized in a variety of media, including AAA video games and music videos, and has applications in communication and training. The company has collaborated with prominent clients such as Warner Brothers and Def Jam Recordings and has received multiple awards for its innovative animation solutions, highlighting its impact on the industry.

Day Zero Diagnostics Inc. is an innovative company focused on transforming infectious disease diagnostics through advanced sequencing technologies. Based in Boston, Massachusetts, the company has developed a rapid diagnostic system that identifies bacterial species and their antibiotic resistance profiles directly from clinical samples. Key technologies include Blood2Bac, which enriches bacterial DNA, and BacDetect, allowing for swift detection of bacterial DNA. Additionally, the company employs machine learning algorithms for genomic antibiotic susceptibility testing and maintains a comprehensive microbial database that integrates genomic sequencing data with resistance profiles. By enabling rapid and accurate diagnoses, Day Zero Diagnostics aims to address critical needs in managing bloodstream infections and sepsis, reducing the time for diagnosis from days to hours and improving patient outcomes through targeted treatments.

Codoxo, formerly known as Fraudscope, is a company dedicated to enhancing the affordability and effectiveness of the healthcare system. It has developed a Forensic AI Platform that employs a patented algorithm to swiftly identify issues and suspicious activities within healthcare plans, surpassing traditional detection methods. This technology facilitates smart investigation and fraud detection, allowing investigators and analysts to gain valuable insights and conduct comprehensive investigations of questionable claims. By utilizing advanced AI-based capabilities, Codoxo aims to ensure that healthcare resources are allocated to genuine patient care, ultimately contributing to a more efficient healthcare environment.

Nucleix Ltd. is a biotechnology company that specializes in the development, manufacture, and marketing of non-invasive molecular cancer diagnostic tests. Founded in 2008 and headquartered in Rehovot, Israel, with an additional office in San Diego, California, Nucleix focuses on detecting cancer through sensitive and specific tests that identify subtle changes in DNA methylation patterns. The company's flagship products include Bladder EpiCheck, a urine test designed for the monitoring of bladder cancer, and Lung EpiCheck, a blood test for the early detection of lung cancer. By leveraging proprietary biomarker assays, Nucleix aims to enhance cancer monitoring and screening capabilities, ultimately improving treatment outcomes for patients. The company has established distribution partnerships in multiple countries, including Israel, the Netherlands, Turkey, Russia, Italy, and Denmark.

Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.

Upgrade, Inc. is an online lending platform based in San Francisco, California, with additional offices in Phoenix, Montreal, and Chicago. Founded in 2016, Upgrade provides access to personal loans and the Upgrade Card, offering consumers affordable credit options. The Upgrade Card combines the benefits of traditional credit cards with the responsible lending characteristics of installment loans, available at numerous retail locations in the U.S. In addition to lending services, Upgrade offers free credit monitoring, alerts, and educational tools designed to help consumers understand and manage their finances effectively. By combining financial products with educational resources, Upgrade aims to promote responsible credit use among mainstream consumers.

Ankyra is a biotech company focused on developing anchored immunotherapy to enhance cancer treatment. The company's innovative approach addresses the challenges associated with traditional cytokine therapeutics, which often face limitations due to widespread immune activation and toxicity when administered systemically. Ankyra utilizes its Anchored Immunotherapy Platform to create ANK-101, a stable complex that combines a modified IL-12 cytokine with an FDA-approved adjuvant, aluminum hydroxide, which helps to retain the cytokine's potent activity at the tumor site. This localized delivery results in targeted inflammation that activates an anti-tumor immune response while minimizing adverse effects. Ankyra aims to optimize the efficacy and safety of its therapies, ultimately improving treatment outcomes for cancer patients.

Acrivon Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision oncology therapeutics. The company employs a proteomics-based platform to identify patients whose tumors are likely to respond positively to specific treatments, thereby enhancing the effectiveness of its drug development efforts. Acrivon's pipeline features its lead program, ACR-368 (prexasertib), which is currently in Phase 2 trials, alongside several preclinical programs targeting key components of DNA damage response and cell cycle regulation, including WEE1 and PKMYT1. By concentrating on complex oncology drug targets that are often not addressed by traditional therapies, Acrivon aims to expedite the advancement of both in-licensed clinical-stage assets and its internally developed programs through accelerated registration trials.

Mekonos Inc. is a biotechnology company founded in 2017 and based in San Francisco, California, specializing in the design, development, and production of gene and cell therapies. The company has created a proprietary cell-engineering platform that utilizes a silicon chip automated architecture to advance the field of genome editing. This innovative system-on-a-chip technology allows for the precise control of individual nanoneedles to inject single cells in a parallel architecture, enabling the industrial-scale production of engineered therapies for a range of genetic diseases, including cancers. Mekonos aims to provide healthcare providers with a reliable and reusable manufacturing system that can deliver various therapeutic molecules across different primary cell types, thus enhancing drug discovery and development processes.

SafeBreach Inc. is a cybersecurity company that specializes in breach and attack simulation (BAS). Founded in 2014 and headquartered in Sunnyvale, California, with an additional office in Tel Aviv, Israel, SafeBreach offers a platform designed to enhance an organization's security posture by simulating real-world attack methods. The platform utilizes a comprehensive Hacker's Playbook, which includes a range of breach techniques derived from actual cyber incidents, to proactively identify vulnerabilities within an enterprise's network, cloud, and endpoints. By mimicking the tactics of cybercriminals, SafeBreach enables businesses to validate their security controls and improve the responsiveness of their security operations center (SOC) analysts. The platform can integrate with various security information and event management systems, ticketing solutions, and automation tools, providing continuous visibility into potential security threats and allowing organizations to address issues before they can be exploited by attackers.

SafeRide Health is a healthcare technology platform that focuses on enhancing medical transportation and care coordination for vulnerable populations. The company provides a comprehensive platform that empowers health plans to manage their members effectively, ensuring greater intelligence and control over services. By utilizing advanced technology and artificial intelligence, SafeRide Health facilitates end-to-end data transparency, which in turn improves patient experiences and outcomes. The platform aims to transform the patient journey, enhance population health, and reduce overall healthcare costs through its innovative solutions, including patented fleet management capabilities tailored to the healthcare industry.

Prilenia is a clinical-stage biotechnology company focused on developing innovative treatments for neurodegenerative and neurodevelopmental disorders. Founded in 2018 and operating from locations in Israel, the Netherlands, and Boston, the company’s primary asset is Pridopidine, an oral drug candidate noted for its established safety profile. Pridopidine demonstrates potential in treating various movement disorders and neurodegenerative diseases that affect both adults and children, aiming to help healthcare institutions preserve functional capacity in patients, including those undergoing early hemodialysis.

Bridgit is an Australian privately owned non-bank lender. At Bridgit, it is our mission to revolutionise property financing and offer Australians a solution that helps them progress in life, without any of the red tape. When it comes to buying property it can be very competitive and difficult to find the perfect home, a Bridgit loan is a great option for homeowners who want to buy on their terms by finding their next home without having to sell first. Through the use of technology we make it easy, with a 5 minute online application, same day approval and no monthly repayments you can focus on the important things. It is all about giving hard working Australians the opportunity to make progress in their lives, without the hold backs.

Hungry Marketplace Inc. is a Washington, D.C.-based platform that connects independent chefs with businesses seeking high-quality catered meals. Founded by Eman Pahlavani, Shy Pahlevani, and Jeff Grass, the company aims to revolutionize the $60 billion business and events catering market by offering a diverse range of curated menus from local chefs. Hungry's platform facilitates the ordering of office lunches and other meal services. The company is committed to community welfare through its 'Fight Against Hunger' initiative, which donates one meal for every two purchased, and its 'WeRecycle' program, which emphasizes environmental sustainability by using biodegradable serving materials. With operations expanding rapidly in cities such as Philadelphia, Atlanta, Boston, and New York City, Hungry aims to broaden its reach to a total of 23 U.S. cities by the end of 2021.

Elephas is a company focused on revolutionizing cancer treatment through its innovative live tumor imaging diagnostics platform. By leveraging advances in cancer biology, multimodal microscopy, engineering, and artificial intelligence, Elephas aims to enhance clinical decision-making and personalize therapy for cancer patients. The company's approach involves the use of human live tumor fragments, allowing clinicians to determine the most effective treatment strategies for individual patients. In doing so, Elephas not only seeks to improve patient outcomes but also to expedite the drug development process, addressing the significant challenges faced in oncology.

JumpCloud, Inc. is a provider of a Directory-as-a-Service platform that simplifies identity management for organizations. Founded in 2010 and based in Louisville, Colorado, the company offers a cloud-based solution enabling secure access to systems, applications, files, and networks from any device or location. Its platform automates server management tasks, including user management, security, compliance, and configuration assessment. JumpCloud allows IT and security teams to manage user identities, devices, and permissions while applying Zero Trust principles. The company serves over 100,000 organizations globally, including more than 3,000 customers such as Cars.com, GoFundMe, and Foursquare. Originally known as SafeInstance, Inc., JumpCloud rebranded in October 2013 to reflect its focus on providing secure and frictionless access to corporate technology resources.

Snyk Ltd. is a software as a service company that specializes in application security, enabling developers to identify and remediate vulnerabilities within their code and associated components. Founded in 2015 and headquartered in London, Snyk offers a suite of tools designed for modern application development, including Snyk Code for static application security testing, container vulnerability management, and infrastructure as code security solutions. The platform seamlessly integrates into developers' workflows, allowing security teams to collaborate effectively with development teams. Snyk's services encompass monitoring application dependencies for vulnerabilities, ensuring licensing compliance, and providing detailed reports and issue tracking. With a client base of 1,200 organizations, including prominent companies like Google and Salesforce, Snyk empowers developers to build secure applications while enhancing overall security posture and productivity. The company also maintains a strategic partnership with Rapid7, further extending its capabilities in the security landscape.

PolyAI Ltd is a company that specializes in developing a conversational artificial intelligence platform aimed at enhancing human-machine voice interactions. Established in 2017 and headquartered in London, United Kingdom, with an additional office in New York, the company focuses on building enterprise voice assistants that engage in natural conversations with customers to address their needs. The platform utilizes advanced machine learning and natural language processing technologies, enabling it to understand and respond to customers effectively, regardless of the variations in their speech. Key features of PolyAI’s platform include multilingual support, dynamic flow design, and task-agnostic capabilities, allowing developers to create seamless and human-like interactions within various digital environments.

Qvella Corporation is a Toronto-based molecular diagnostics company founded in 2009 by a group of scientists and engineers. The company focuses on transforming clinical microbiology by significantly reducing the time required to obtain results for bloodstream infections. Qvella's innovative Field Activated Sample Treatment (FAST™) technology employs a novel electrical lysing technique, known as e-lysis™, which facilitates the rapid and fully automated detection of infectious agents directly from unenriched biological samples. This capability allows clinicians to identify microorganisms in infected whole blood samples without the lengthy sample processing typically required, ultimately enhancing patient outcomes and saving lives.

#Paid is a technology company that offers a creative marketing platform designed to facilitate collaboration between brands and social media creators. The platform enables brands to connect with a diverse array of artists, travelers, storytellers, and photographers globally, allowing for authentic product placements on social media. By transforming creator-generated content into paid advertisements, #Paid promotes engaging partnerships that enhance brand visibility and reach. With a focus on meaningful collaborations, the company streamlines the process for brands looking to leverage the influence of creators in their marketing campaigns.

DICE Therapeutics is a biopharmaceutical company dedicated to developing novel oral therapeutic candidates aimed at treating chronic diseases, particularly in immunology. Utilizing its proprietary DELSCAPE technology platform, DICE focuses on creating selective oral small molecules that can effectively modulate protein-protein interactions, similar to the efficacy of existing systemic biologics. The company's lead candidate, S011806, targets interleukin-17 (IL-17), a key pro-inflammatory molecule associated with various immunological conditions. Additionally, DICE is advancing oral therapies aimed at α4ß7 integrin and αVß1/αVß6 integrin, which are intended for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively. Through its innovative approach, DICE Therapeutics aims to bring effective oral treatments to patients suffering from chronic inflammatory diseases.

Gusto is a software-as-a-service (SaaS) company focused on Human Capital Management (HCM). It offers a comprehensive, cloud-based platform that provides a range of HR and payroll services designed for small businesses. Key features of Gusto’s platform include payroll processing, benefits administration, time and attendance tracking, and employee onboarding. Additionally, it supports the management of employee benefits such as health, dental, and vision insurance. By streamlining these essential functions, Gusto aims to simplify the complexities of human resource management, enabling businesses to effectively meet their employees' needs.

Exo is a medical device startup focused on developing a handheld ultrasound platform for imaging and therapeutic applications. The company aims to provide affordable and user-friendly medical imaging solutions for healthcare professionals globally. By integrating advanced nano-materials, innovative sensor technologies, and sophisticated signal processing with the cost efficiencies of semiconductor manufacturing, Exo significantly lowers the costs associated with medical imaging. This technology allows healthcare providers to make vital, real-time decisions that enhance patient outcomes. Exo's commitment to high-quality, accessible imaging represents a significant advancement in medical technology, making effective diagnostic tools available at an unprecedented price point.

BlackBuck is a leading logistics company based in India, founded in 2015, that leverages technology to transform the trucking industry. By moving offline trucking operations online, BlackBuck connects shippers with truckers, providing a seamless platform for booking loads and facilitating payments, insurance, and financial services. The company's comprehensive solutions enhance reliability and efficiency in transportation, benefiting both truckers and shippers. BlackBuck's platform features tools for price discovery, route optimization, in-transit tracking, and timely delivery assurance, which collectively help clients improve business productivity. With a workforce of around 2,000 employees, BlackBuck has established itself as the largest trucking network in India and has garnered recognition for its innovative approach, earning awards such as CNBC-TV18's Young Turks Startup of the Year and Zee Business's Company of the Year in Logistics in 2018. The company is also featured in a case study by Harvard Business School, underscoring its impact on the logistics landscape.

Wugen is a biotechnology company focused on developing innovative off-the-shelf cellular therapies for cancer treatment. The company specializes in natural killer (NK) cell and CAR-T immuno-oncology therapies, utilizing healthy donor cells that are manipulated to enhance their ability to target and eliminate cancer cells. Wugen's proprietary Moneta platform, along with its expertise in genomic engineering, allows for the creation of a new class of memory NK cell therapies aimed at addressing solid tumors, acute myeloid leukemia, and T-cell malignancies. Through its advancements, Wugen seeks to provide effective treatment options for patients facing life-threatening tumors.

Primer is an internet company that specializes in leveraging artificial intelligence to analyze extensive collections of text data. Its machine intelligence platform employs advanced machine learning and natural language processing techniques to automate the analysis of large datasets. By parsing and collating documents in multiple languages, Primer enables businesses to uncover insights and generate reports that are on par with human analysts. This capability helps organizations bridge the intelligence gap and respond more effectively to emerging trends in their respective fields.

Nubank is a prominent digital bank revolutionizing finance with its customer-centric approach. It provides a variety of services, including credit cards, personal loans, and digital payments, all accessible through a simple mobile app. Known for transparency, ease of use, and low fees, Nubank aims to empower users with innovative solutions for better financial management.

Outreach Inc. is a Seattle-based company that specializes in sales engagement solutions designed to enhance revenue growth by streamlining customer interactions across various channels, including email, voice, and social media. Founded in 2011, Outreach offers a platform that utilizes machine learning to automate repetitive sales tasks, optimize communication, and provide real-time insights based on buyer sentiment. Its features include account-based sales solutions, task management, and comprehensive tracking of email and activity metrics. Outreach's clientele encompasses major companies such as Zoom, Okta, Adobe, and Microsoft, which depend on its technology to improve sales efficiency and effectiveness. The company also maintains an office in London, United Kingdom.

Klaviyo, Inc. is a technology company headquartered in Boston, Massachusetts, with an additional office in London, United Kingdom. Founded in 2012, Klaviyo specializes in providing an email marketing software platform designed to help businesses grow through effective marketing automation. Its features include a library of best practice emails, segmentation tools, analytics, customer profiles, and support for various campaigns such as abandoned cart reminders and personalized follow-ups. Klaviyo's platform integrates with customer data sources to deliver tailored messaging across email, SMS, and push notifications, enabling businesses to engage with customers at the right time. The company utilizes machine learning and artificial intelligence to enhance its services and measures performance to optimize marketing efforts. Klaviyo generates revenue through subscription sales for its software-as-a-service platform, focusing primarily on the eCommerce sector.

Lyra Health, Inc. is a digital health company based in Burlingame, California, founded in 2015. It operates a platform that connects employers with a curated network of mental health care providers, including therapists and coaches. Lyra's innovative technology matches employees to the appropriate mental health resources based on their individual needs and preferences, enhancing access to high-quality care. The platform employs clinical measures to assess symptom improvement for common mental health issues, leading to significantly better outcomes compared to traditional plans. By offering live video therapy, coaching, and digital self-care tools, Lyra facilitates a comprehensive treatment journey for its members, resulting in increased engagement and support throughout the mental health process.

Boom Entertainment is a technology company that specializes in developing a sports gaming application tailored for the sports betting industry. The company focuses on creating casual gaming experiences and offers both real-money and free-to-play online sports and casino games. Collaborating with professional sports leagues, media companies, and casino operators, Boom Entertainment aims to provide innovative gaming solutions that enhance user engagement. Its applications are designed to support business-to-business providers, facilitating access to real-money games for major casino operators.

Tellius, Inc. is an AI-powered business analytics platform established in 2015 and headquartered in Reston, Virginia. The platform is designed to help enterprises accelerate data-driven insights and decision-making by integrating artificial intelligence with a search-enabled interface for ad hoc exploration. Unlike traditional business intelligence tools, Tellius employs a distributed architecture that leverages Apache Spark, enabling it to handle big data efficiently. The platform automates the interpretation and analysis of data through machine learning, identifying hidden correlations, trends, and anomalies. Users can pose questions about their business data and receive immediate insights, which are presented as suggested visualizations and predictive models, facilitating a more comprehensive understanding of their operations.

Biosplice Therapeutics is a company focused on medical research and development in tissue-level regeneration. Its platform, which originated from small molecule-based modulation of the Wnt signaling pathway, is designed to create therapeutics for a variety of degenerative diseases, including osteoarthritis and certain cancers. By discovering new biological targets and processes, Biosplice Therapeutics aims to develop innovative small molecule drugs that could provide curative therapies for multiple conditions. The company's objective is to enhance patient health through a comprehensive technology platform dedicated to modulating regenerative pathways.

Snyk Ltd. is a software as a service company that specializes in application security, enabling developers to identify and remediate vulnerabilities within their code and associated components. Founded in 2015 and headquartered in London, Snyk offers a suite of tools designed for modern application development, including Snyk Code for static application security testing, container vulnerability management, and infrastructure as code security solutions. The platform seamlessly integrates into developers' workflows, allowing security teams to collaborate effectively with development teams. Snyk's services encompass monitoring application dependencies for vulnerabilities, ensuring licensing compliance, and providing detailed reports and issue tracking. With a client base of 1,200 organizations, including prominent companies like Google and Salesforce, Snyk empowers developers to build secure applications while enhancing overall security posture and productivity. The company also maintains a strategic partnership with Rapid7, further extending its capabilities in the security landscape.

Luminoah is a medical device company focused on transforming the enteral feeding market through its innovative platform for personalized enteral nutrition. The company has developed a closed-loop system that integrates a wearable device with durable medical equipment and consumable nutrition pouches. This system allows for real-time tracking of feed status online, enabling healthcare professionals to remotely monitor patients and assess clinical outcomes effectively. By enhancing chronic disease care, Luminoah aims to improve the quality of life for individuals requiring enteral nutrition.

WireWheel, Inc. is a software company specializing in data privacy management solutions, designed to assist organizations in complying with various data protection regulations such as the EU GDPR and HIPAA. Established in 2016 and headquartered in Arlington, Virginia, WireWheel offers a cloud-based platform that integrates machine learning and data science to streamline privacy program management and subject rights request handling. The platform facilitates the automatic mapping of public cloud assets and aids in managing third-party relationships, enabling organizations to effectively navigate compliance obligations while maximizing the value of their data assets. WireWheel's innovative approach positions its clients to operationalize privacy effectively within their enterprises.

Personal Genome Diagnostics, Inc. is a biotechnology company focused on patient-specific analyses of cancer genomes. Established in 2010 and headquartered in Baltimore, Maryland, the company has pioneered technologies for non-invasive "liquid biopsy" approaches, allowing for the detection of tumor-specific alterations in circulating cell-free DNA. Its offerings include the METDetect Assay for identifying MET gene amplifications, LungSelect for detecting actionable genetic alterations in non-small cell lung cancer patients, and PGDx elio plasma resolve, which analyzes various genetic mutations from plasma samples. Additionally, Personal Genome Diagnostics provides RNAcomplete, enabling researchers to extract both RNA and genomic DNA from a single tissue sample, and CancerXOME, which captures and analyzes coding regions of genes. The company collaborates with institutions like Mayo Clinic and partners with KingMed Diagnostics to enhance its research and diagnostic capabilities, thereby empowering oncologists and researchers with crucial genomic insights to combat cancer.

Earli is a company focused on developing innovative cancer treatment devices that utilize synthetic biomarkers for early cancer detection. The company's approach involves a novel gene therapy technique known as Synthetic Biopsy, which prompts cancer cells to produce synthetic, non-human biomarkers. These biomarkers can be detected through various means, including blood, urine, or breath, allowing for timely tracking and treatment of cancer. By facilitating the early identification of cancer when it is still homogeneous, Earli aims to significantly enhance survival rates. Their technology not only aids in detection but is also applicable for therapeutic interventions, thereby personalizing treatment and improving patient outcomes.

DICE Therapeutics is a biopharmaceutical company dedicated to developing novel oral therapeutic candidates aimed at treating chronic diseases, particularly in immunology. Utilizing its proprietary DELSCAPE technology platform, DICE focuses on creating selective oral small molecules that can effectively modulate protein-protein interactions, similar to the efficacy of existing systemic biologics. The company's lead candidate, S011806, targets interleukin-17 (IL-17), a key pro-inflammatory molecule associated with various immunological conditions. Additionally, DICE is advancing oral therapies aimed at α4ß7 integrin and αVß1/αVß6 integrin, which are intended for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively. Through its innovative approach, DICE Therapeutics aims to bring effective oral treatments to patients suffering from chronic inflammatory diseases.

Cytrellis Biosystems, Inc. is a clinical stage medical technology company focused on designing and developing innovative devices for dermatology, scar reduction, and aesthetic medicine. Founded in 2011 and headquartered in Sherborn, Massachusetts, the company aims to address age-related skin changes through non-surgical solutions. Its products are specifically engineered to remove sagging skin without the need for invasive procedures or scarring, thereby offering aesthetic practitioners enhanced capabilities to improve the appearance of aging skin. Cytrellis Biosystems is dedicated to advancing the field of aesthetic medicine with its cutting-edge technologies.

Coagulo is transforming medicine with the first portable and connected precision-medicine platform for smarter management of coagulation, enabling better healthcare outcomes for everyone.

StockX LLC is an online marketplace founded in March 2015 and headquartered in Detroit, Michigan, that facilitates the buying and selling of limited edition and high-demand sneakers. It operates a live bid/ask platform, allowing users to anonymously engage in transactions with stock market-like visibility. The marketplace offers features such as historical price and volume metrics, real-time bids and offers, and time-stamped trades, enabling users to track their sneaker collections and compare them with others on the platform. Additionally, StockX provides in-depth market analysis and news, allowing consumers to assess the value of their products and ensuring that sellers receive fair deals.

Uhnder Inc. is a technology company that specializes in developing innovative products for sensing, cognition, and communication within the Internet of Things (IoT) market. Founded in 2015 and headquartered in Austin, Texas, with additional engineering and operations in St. Louis, Uhnder is recognized for its digital automotive radar-on-chip. This technology serves as a more accurate and reliable alternative to traditional light detection and ranging (lidar) systems, enhancing the safety and responsiveness of autonomous vehicles. The chip is designed to prevent collisions, alert drivers to potential hazards, and facilitate quick localization for navigation. By offering this advanced solution, Uhnder aims to significantly improve the automation capabilities of manufacturers in the automotive sector.

Papercup is a London-based company that specializes in automating the dubbing and translation of video content using advanced artificial intelligence. Its software employs a combination of Bayesian neural networks and speech synthesis to create synthetic voice-overs that closely resemble human speech. This technology allows video creators to produce content in their original language while enabling users to translate videos into their preferred languages. Papercup's platform streamlines the localization process, making it faster and more cost-effective compared to traditional methods. The company also incorporates a quality assurance system where professional translators review the voiceovers, ensuring high accuracy and broadcast-quality results. By enhancing video accessibility, Papercup aims to help content owners engage with a global audience more effectively.

Brightflag is a technology company that specializes in AI-powered enterprise legal management software, aimed at helping organizations manage their legal expenditures effectively. Founded in 2014, the company serves in-house legal teams and their vendors from offices in Dublin, New York, and Sydney. Brightflag's platform offers capabilities such as matter management and e-billing reporting, utilizing advanced language analysis technologies to scrutinize incoming legal invoices. This enables clients to identify opportunities for cost reductions, optimize fee arrangements, and gain comprehensive visibility into their legal spending. By processing billions of dollars in legal spend annually, Brightflag has facilitated substantial savings and streamlined administrative tasks for its users, enhancing their ability to control outside counsel costs and efficiently manage invoice approvals.

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Livermore, California, focused on discovering and developing therapeutics and diagnostics for Alzheimer's disease and related neurodegenerative conditions. The company is advancing a targeted immunotherapy drug candidate, ACU193, which selectively targets amyloid-beta oligomers, believed to be a significant contributor to the disease process. Acumen employs a sensitivity assay to measure soluble amyloid-beta oligomer levels in cerebrospinal fluid, which aids in patient enrollment for clinical trials. The Phase 1 clinical trial for ACU193, initiated in the second quarter of 2021, aims to evaluate the drug's safety, tolerability, pharmacokinetics, and target engagement among patients with mild cognitive impairment and mild dementia due to Alzheimer's disease. Results from this trial are anticipated by the end of 2022. Founded in 1996, Acumen Pharmaceuticals is committed to developing innovative approaches to address the challenges posed by Alzheimer's disease.

Scopely, Inc. is an interactive entertainment and video game company based in Culver City, California, founded in 2011. It specializes in developing and publishing mobile and tablet games for both casual and core gamers globally. Scopely is known for its popular franchises, such as "Star Trek™ Fleet Command," "MARVEL Strike Force," "Stumble Guys," and "Yahtzee With Buddies." The company utilizes its proprietary technology platform, Playgami™, to create immersive gaming experiences, with a focus on player engagement and long-lasting enjoyment. Scopely also offers a range of services including game design, live operations, marketing, and analytics, supporting a diversified portfolio within the mobile gaming industry. With operations in various international markets, including Asia-Pacific, EMEA, and North America, Scopely has established itself as a significant player in the interactive entertainment sector.

Totient Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2016. It specializes in data analysis for drug discovery and development, focusing on identifying novel tissue-specific antigens using tertiary lymphoid structures (TLSs). The company employs advanced machine learning and immunoinformatics to extract valuable insights from large datasets, facilitating the rapid assembly of high-affinity antibody candidates. Totient's platform is versatile, enabling the development of therapeutics aimed at treating cancer, autoimmune diseases, infections, and viral conditions. By leveraging knowledge from recent research and patient-derived tissues with exceptional immune responses, Totient aims to deliver effective antibody therapeutics for a range of medical applications.

BYJU'S is a prominent global ed-tech company founded in India in 2011, dedicated to providing adaptive and engaging learning solutions to over 150 million students worldwide. The company aims to make high-quality education accessible to learners of all ages through its flagship product, BYJU's: The Learning App, and a diverse portfolio that includes brands such as Disney-BYJU's Early Learn, BYJU's FutureSchool, and WhiteHat Jr. BYJU'S employs personalized learning methodologies that cater to individual learning styles and paces, supported by a network of over 12,000 teachers. The platform utilizes original content, watch-and-learn videos, animations, and interactive simulations to create a contextual and practical learning experience. Additionally, BYJU'S has formed innovative partnerships with major companies like Disney and Google to enhance engagement. Headquartered in India, BYJU'S operates in more than 21 countries and offers programs in over 8 languages, further solidifying its position as a leader in the education technology sector.

Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.